



**GSK2636771** 

**Catalog No: tcsc0747** 

Z	Available Sizes
Size:	5mg
Size:	10mg
Size:	50mg
Size:	100mg
	Specifications
<b>CAS N</b> 13725	<b>lo:</b> 40-25-4
Form	<b>ula:</b> 2 <sup>F</sup> 3 <sup>N</sup> 3 <sup>O</sup> 3
Pathv	
<b>Targe</b> PI3K	t:
Purity >98%	y / Grade:
<b>Solub</b>	ility: : 10.6 mg/mL (24.46 mM; Need ultrasonic and warming)
<b>Obse</b> : 433.42	rved Molecular Weight:

## **Product Description**

GSK2636771 is a potent, selective and oral inhibitor of **PI3K\beta** with a **K\_i** of 0.89 nM and an **IC\_{50}** of 5.2 nM, showing 900-fold





selectivity over p110 $\alpha$  and p110 $\gamma$ , and 10-fold selectivity over p110 $\delta$  isoforms.

In Vitro: GSK2636771 treatment causes cell viability significantly more decreased in the control cells (p110β-reliant PTEN-deficient PC3 prostate and BT549 and HCC70 breast cancer cell lines) than in PTEN-mutant and PTEN wild-type EEC cells. Inhibition of p110β by GSK2636771 or AZD6482 leads to a marked decrease of AKT phosphorylation only in the control prostate and breast cancer cell lines, whereas only marginal effects on AKT activation are observed in EEC cells<sup>[1]</sup>.

In Vivo: GSK2636771 is a p110 $\beta$  inhibitor, and the p110 $\beta$  primes cells for response to growth factor stimulation. While p110 $\beta$  inhibition suppresses cell and tumor growth, dual targeting of p110 $\alpha/\beta$  enhances apoptosis and provides sustained tumor response in mice model<sup>[2]</sup>.

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!